Oral Vancomycin Followed by Fecal Transplant Versus Tapering Oral Vancomycin

NCT ID: NCT01226992

Last Updated: 2014-12-08

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 81 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-10-31
• Study Completion Date: 2014-10-31

Brief Summary

Recurrent CDI is a growing problem with few treatment options that provide lasting effect. Fecal transplantation has been shown in several case series to be successful in controlling recurrent CDI. The current study is a non-blinded, randomized controlled trial comparing fecal transplantation with a 6 week taper of oral vancomycin for the treatment of refractory CDI. Approximately 146 patients will be enrolled over one year. Participants in the study will be followed for 120 days, and will be given the opportunity to cross over to the alternative intervention arm if a relapse in symptoms occurs. The primary outcome measure will be recurrence of toxin-confirmed CDI within 120 days of starting the intervention. Secondary outcomes include: early recurrence of symptoms within 14 days, relapse within 120 days (same strain of C. difficile), attributable mortality, hospitalization and serious adverse events.

Detailed Description

The proposed trial is a single-centre, phase II/III, open, parallel-group, randomized controlled trial. To have an evaluable population of 114 participants and assuming a 20% loss to follow-up, approximately 146 patients will be randomized in a 1:1 ratio to receive either approximately 2 weeks of oral vancomycin followed by a single fecal transplant via enema (hereon referred to as the "fecal transplant arm") or a 6-week taper of oral vancomycin (hereon referred to as the "vancomycin taper arm"). The 2 weeks of vancomycin pre-treatment in the fecal transplant arm will allow for a fecal transplant donor to be screened for potentially transmissible infectious diseases (clinically and through blood and stool tests), in order to ensure appropriateness and safety of donation.

If patients fail treatment during the follow-up period of 120 days, they will be offered the opportunity to cross over to the alternate treatment arm. Those who cross over will be followed for an additional 120 days from the second intervention.

Participants will be assessed clinically for recurrence in CDI symptoms and adverse events at the following time points after the intervention: 4 days, 7 days, 3 weeks, 6 weeks, 12 weeks and 16 weeks. All recurrences of CDI symptoms will be investigated with C. difficile laboratory testing to confirm the etiology of these symptoms.

Analysis will be intention to treat. An interim analysis may take place after completion of follow-up of 30 patients. This interim analysis is meant to establish the safety and feasibility of the study, not measure efficacy. Although there were no formal sample size calculations to assess safety of the procedure, with a sample size of 70 participants, an adverse event rate, for example of 2.5%, can be detected with a probability of 0.83 for the fecal transplantation group.

Conditions

Recurrent Clostridium Difficile Infection; Laboratory Confirmed Clostridium Difficile Infection

Keywords

Clostridium difficile; Fecal Transplant; Recurrent Diarrhea; Abdominal distension/bloating; Fever

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Fecal Transplant

2 weeks of oral vancomycin pre-treatment followed by single dose fecal transplant administered by rectal enema. Fecal transplant (slurry) consists of 50 grams healthy donor stool blended in 500ml of Normal Saline.

Group Type: EXPERIMENTAL

Fecal Transplant

Intervention Type: BIOLOGICAL

Fecal slurry 50 grams stool in 500ml normal saline

Oral Vancomycin Taper

2 weeks of oral vancomycin pre-treatment followed by 6-week taper of oral vancomycin

Group Type: ACTIVE_COMPARATOR

Vancomycin

Intervention Type: DRUG

Oral Vancomycin:

Dose: 125 mg po qid x 2 weeks then 125 mg po bid x 1 week then 125 mg po od x 1 week then 125 mg po q every other day x 1 week then 125 mg po q every third day x 1 week then discontinue Route: oral

Interventions

Vancomycin

Oral Vancomycin:

Dose: 125 mg po qid x 2 weeks then 125 mg po bid x 1 week then 125 mg po od x 1 week then 125 mg po q every other day x 1 week then 125 mg po q every third day x 1 week then discontinue Route: oral

Intervention Type: DRUG

Fecal Transplant

Fecal slurry 50 grams stool in 500ml normal saline

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Laboratory or pathology-confirmed diagnosis of recurrent C. difficile infection (CDI) with symptoms within the previous 60 days. Recurrent CDI is defined as:

• >/=2 episodes of CDI. Eligible patients must have had at least one treatment course with oral vancomycin (minimum 10 days of 500 mg total daily oral vancomycin).

Symptoms of CDI include:

• Diarrhea (see below) OR
• Abdominal pain AND abdominal distension/bloating AND fever, systemic illness with no other reason for these symptoms

Diarrhea will be self-reported and is defined as:

• at least 6 watery feces in 36 hours OR
• 3 unformed feces in 24 hours for minimum 2 days OR
• 8 unformed feces over 48 hours

• Age 18 years or older
• Signed informed consent
• Able to travel to clinic for follow-up visit and/or adhere to study procedures
• Agrees to abstain from taking probiotic supplementations for medicinal reasons for the duration of the study and follow-up period. To clarify, dietary intake is acceptable (e.g. non-supplemented yogurt).

Exclusion Criteria

• Planned participation in another clinical trial
• Patients with conditions such as neutropenia, graft versus host disease or severe immunocompromise, in whom enemas are contraindicated
• More than one episode of CDI that has been severe or rapid in onset, resulting in:

• intensive care unit admission
• Evidence of active, severe colitis (ie. ongoing diarrhea not responsive to oral vancomycin; hemorrhagic colitis) such that an enema is contraindicated (note that such patients may be eligible once their colitis is under control)
• Unable to tolerate fecal transplantation procedure for any other reason
• Hypersensitivity or intolerance to oral vancomycin
• Patients with underlying chronic gastrointestinal diseases that cause diarrhea, such as:
• Inflammatory bowel disease
• Short gut syndrome
• Severe motility disorders
• Severe diverticular disease
• Other chronic diarrhea NYD
• Unable to record frequency of bowel movements
• Receiving an investigational medication
• Planned therapy in the next 120 days that may cause diarrhea (example: chemotherapy)
• Planned surgery requiring perioperative antibiotics within 120 days
• Pregnancy
• Requires the regular use of medications that affect bowel motility before onset of CDI (example: metoclopramide, narcotics, loperamide)
• Serious bleeding disorder, anticoagulant use that cannot be stopped temporarily for procedure (in consultation with prescribing physician) or serious platelet disorder (platelet counts below 50).
• Any condition that, in the opinion of the investigator, would pose a health risk to the subject.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University Health Network, Toronto

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Susy Hota, MD FRCPC

Role: PRINCIPAL_INVESTIGATOR

Infectious Disease, Infection Prevention and Control, Epidemiologist

Susan Poutanen, MD MPH FRCPC

Role: STUDY_DIRECTOR

Infectious Disease, Microbiologist

Locations

University Health Network

Toronto, Ontario, Canada

Countries

Canada

References

Hota SS, Sales V, Tomlinson G, Salpeter MJ, McGeer A, Coburn B, Guttman DS, Low DE, Poutanen SM. Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial. Clin Infect Dis. 2017 Feb 1;64(3):265-271. doi: 10.1093/cid/ciw731. Epub 2016 Nov 9.

Reference Type: DERIVED

PMID: 28011612 (View on PubMed)

Other Identifiers

9424-U0288/2-25C 124081

Identifier Type: OTHER

Identifier Source: secondary_id

UHN # 08-0440

Identifier Type: -

Identifier Source: org_study_id